Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/89286
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Pirfenidone for the treatment of idiopathic pulmonary fibrosis |
Autor: | Xaubet, Antoni; Serrano-Mollar, Anna CSIC ORCID; Ancochea, Julio | Palabras clave: | Anti-fibrotic drugs Idiopathic pulmonary fibrosis Pirfenidone |
Fecha de publicación: | feb-2014 | Editor: | Informa Healthcare | Citación: | Expert Opinion on Pharmacotherapy 15(2): 275-281 (2014) | Resumen: | [Introduction]: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and lethal fibrosing interstitial pneumonia. The median survival from the onset of the symptoms is 2.8 – 4.2 years and the 5-year survival rate is 20%. Its poor prognosis, combined with the scarcity of treatment options, provides a strong rationale for the development of novel therapeutic strategies. During the past decade there has been a huge rise in clinical trials with anti-fibrotic drugs, although only pirfenidone (Esbriet) has shown a beneficial effect. [Areas covered]: This article reviews the medical literature on the effectiveness and safety of pirfenidone in IPF, by means of a PubMed search from 1995 to present, completed with some data on file from the manufacturer. [Expert opinion]: Pirfenidone is the only anti-fibrotic drug approved for the treatment of IPF. Pirfenidone provides a meaningful clinical effect on reductions in the decrease in forced vital capacity (FVC), six-minute walk test (6MWT) distance and mortality, and it improves the progression-free survival in IPF patients with mild-to-moderate disease. Pirfenidone is well tolerated, with the most common side-effects being gastrointestinal discomfort and photosensitivity. Pirfenidone has a favorable benefit-risk profile and represents a suitable treatment option for patients with mild-to-moderate IPF. | Descripción: | El pdf del artículo es la versión pre-print. | Versión del editor: | http://dx.doi.org/10.1517/14656566.2014.867328 | URI: | http://hdl.handle.net/10261/89286 | DOI: | 10.1517/14656566.2014.867328 | ISSN: | 1465-6566 | E-ISSN: | 1744-7666 |
Aparece en las colecciones: | (IIBB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Pirfenidone for the.pdf | 449,76 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
25
checked on 18-abr-2024
WEB OF SCIENCETM
Citations
22
checked on 25-feb-2024
Page view(s)
486
checked on 18-abr-2024
Download(s)
741
checked on 18-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.